Drug Type Monoclonal antibody |
Synonyms- |
Target |
Action inhibitors |
Mechanism STEAP1 inhibitors(Six-transmembrane epithelial antigen of the prostate 1 inhibitors), STEAP2 inhibitors(STEAP2 metalloreductase inhibitors) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
License Organization- |
Drug Highest PhasePreclinical |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Metastatic Prostate Carcinoma | Preclinical | Canada | 29 Apr 2025 |